Peptides for Type 2 Diabetes — Evidence Review
Type 2 diabetes has the deepest peptide evidence base of any condition we cover. The incretin agonists — semaglutide, tirzepatide, retatrutide, liraglutide — have transformed diabetes management…
Type 2 diabetes has the deepest peptide evidence base of any condition we cover. The incretin agonists — semaglutide, tirzepatide, retatrutide, liraglutide — have transformed diabetes management since the late 2010s, with multiple large randomized trials, FDA approvals, and post-marketing surveillance data running into hundreds of thousands of patient-years.
This guide reviews the peptides with the strongest evidence, the supporting cast, and the open questions.
Peptides with the strongest evidence
Semaglutide (Ozempic, Wegovy, Rybelsus)
GLP-1 receptor agonist. FDA-approved for type 2 diabetes (Ozempic, Rybelsus oral) and weight management (Wegovy). The SUSTAIN trial program demonstrated sustained HbA1c reduction (~1.5–1.8%) and meaningful weight loss in T2D patients. The SELECT cardiovascular outcomes trial (Lincoff et al., NEJM 2023) showed a 20% relative reduction in MACE in overweight/obese non-diabetic patients with cardiovascular disease — establishing CV benefit beyond glycemic control.
Mechanism: GLP-1 receptor agonism slows gastric emptying, suppresses postprandial glucagon, enhances glucose-dependent insulin secretion, and reduces appetite via central pathways.
Side effect profile is dominated by GI symptoms (nausea, vomiting, diarrhea), most pronounced during titration. Hypoglycemia risk is low when used as monotherapy but rises substantially when stacked with insulin or sulfonylureas — dose adjustments are required.
Tirzepatide (Mounjaro, Zepbound)
Dual GIP/GLP-1 receptor agonist. FDA-approved for T2D (Mounjaro) and weight management (Zepbound). The SURPASS trial program demonstrated superior glycemic control to semaglutide, insulin glargine, and insulin degludec. SURMOUNT-1 showed weight loss approaching 22% of baseline body weight at the 15 mg dose over 72 weeks — outcomes that previously required bariatric surgery.
The GIP component contributes to weight loss and glycemic control through mechanisms not fully characterized. Cardiovascular outcomes data is emerging (SURPASS-CVOT in progress).
GI side effects similar to semaglutide; titration over 4–5 months is typically required to minimize tolerability issues.
Retatrutide
Triple agonist (GIP, GLP-1, glucagon). Phase 2 data (Jastreboff et al., NEJM 2023) showed 24% mean weight reduction at 48 weeks at the 12 mg dose — exceeding tirzepatide's reported figures. T2D-specific Phase 3 trials (TRIUMPH program) are in progress.
The glucagon receptor component is the differentiator: it adds direct hepatic glucose handling and energy expenditure effects to the incretin action. Whether this translates to better glycemic outcomes than tirzepatide head-to-head is the question Phase 3 will answer.
Liraglutide (Victoza, Saxenda)
First-generation GLP-1 (daily injection). Largely superseded by weekly agonists for new starts but remains relevant when weekly dosing isn't tolerated or when faster pharmacokinetic clearance is needed (e.g., bridging to pregnancy). The LEADER trial established CV benefit in T2D patients with established CV disease.
Supporting cast
MOTS-c
Mitochondrial-derived peptide that improves insulin sensitivity in animal models. A small number of human studies have explored metabolic effects. Not approved, not established for T2D — but plausible enough mechanistically that it appears in research-protocol discussions.
Where to source
For semaglutide and tirzepatide, the post-shortage compounding landscape has changed substantially. FDA enforcement against compounded GLP-1 agonists has tightened since 2024. Consumers should:
- Use FDA-approved branded products (Ozempic, Mounjaro, Wegovy, Zepbound) where insurance and supply allow
- For research-use sourcing: Semaglutide vendor rankings, Tirzepatide vendor rankings, Retatrutide vendor rankings
The top-ranked vendors meet purity ≥99.0% on third-party HPLC and publish recent COAs.
What we don't know
- Long-term durability of glycemic control after discontinuation (most patients regain weight and HbA1c rises within 12 months of stopping)
- Whether triple agonists outperform dual agonists at equivalent weight loss on T2D-specific endpoints
- Optimal sequencing of GLP-1 / dual / triple agonists across the disease course
- Whether early initiation in prediabetes prevents progression (PREVENT-T2D-style trials in design)
- Long-term safety beyond ~10 years of continuous use
Methodology
Read the full methodology for our scoring rubric and source-data attribution.
This page is educational. T2D management is a clinical decision that requires a treating physician — endocrinologist, internist, or family medicine — with access to your full medical history.